Superworth

Lipocine EPS LPCN

Diluted earnings per share by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
−$1.87
Latest quarter, Q2 FY26
−$0.32
Fiscal year 2025
−$1.77

Lipocine's earnings per share was −$1.87 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.32.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.77n/a
FY2024−$0.01n/a
FY2023−$3.14n/a
FY2022−$2.24n/a
FY2021−$0.34n/a
FY2020−$6.97n/a
FY2019−$8.67n/a
FY2018−$9.35n/a
FY2017−$17.68n/a
FY2016−$17.68n/a
FY2015−$18.53n/a
FY2014−$27.20n/a
FY2013−$23.46n/a
FY2012−$4.59n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.32n/a−$1.87
Q1 FY26−$0.54n/a−$1.96
Q4 FY25−$0.42−227%−$1.77
Q3 FY25−$0.59n/a−$1.02
Q2 FY25−$0.41n/a−$0.87
Q1 FY25−$0.35−153%−$1.02
Q4 FY24$0.33n/a−$0.01
Q3 FY24−$0.44n/a−$0.77
Q2 FY24−$0.56n/a−$1.60
Q1 FY24$0.66n/a−$1.72
Q4 FY23−$0.43n/a−$3.14
Q3 FY23−$1.27n/a−$3.14

Against its peers

Companies in Drug Manufacturers - General nearest Lipocine's size, closest first, today.

CompanyEPS, 12 monthsGrowth
LPCNLipocine−$1.87
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Lipocine

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.